Ipamorelin vs Ghrp 2
Which Is Right for You? Complete Comparison (2026)
Ipamorelin vs GHRP-2 comparison — selective GH release without cortisol vs higher GH peaks with cortisol and prolactin elevation, dosing protocols.
Ipamorelin vs Ghrp 2: At a Glance
- ✓Selective growth hormone releasing peptide (GHRP)
- ✓Stimulates pituitary GH release via ghrelin/GHS-R1a receptor
- ✓Does not significantly elevate cortisol, prolactin, or aldosterone
- ✓Produces a clean GH pulse similar to natural secretion
- ✓Half-life approximately 2 hours — administered 2-3x daily
- ✓Potent growth hormone releasing hexapeptide (GHRP)
- ✓Stimulates GH release via ghrelin/GHS-R1a receptor
- ✓Stronger GH pulse than Ipamorelin but less selective
- ✓Increases appetite, cortisol, and prolactin levels
- ✓Half-life approximately 15-30 minutes
Detailed Comparison
| Feature | Ipamorelin | Ghrp 2 |
|---|---|---|
| Mechanism | Growth hormone secretagogue (selective GHRP) | Growth hormone releasing hexapeptideBest |
| Dosing | 200-300 mcg SC 2-3x daily | 100-300 mcg SC 2-3x daily |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Half-life | ~2 hours | ~15-30 minutes |
| FDA Status | Not FDA-approved — research peptide | Not FDA-approved — used diagnostically in Japan |
| Key Trial | Raun K et al. Eur J Endocrinol 1998 — demonstrated selective GH release | Howard AD et al. Science 1996 — identified the GHS receptor |
| Side Effects | Headache, flushing, dizziness, injection site irritation — generally well-tolerated | Increased appetite, cortisol/prolactin elevation, water retention, flushing |
Which Should You Choose?
Ipamorelin (growth hormone secretagogue (selective ghrp)) and GHRP-2 (Pralmorelin) (growth hormone releasing hexapeptide) serve different clinical roles despite both being in the GH secretagogue space. Ipamorelin selective gh secretagogue that stimulates gh release from the pituitary via ghrelin receptor without significantly raising cortisol, prolactin, or aldosterone. GHRP-2 (Pralmorelin) potent gh secretagogue acting on ghrelin receptor.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Making an Informed Choice Between Ipamorelin and Ghrp 2
Choosing between Ipamorelin and Ghrp 2 depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.
Head-to-head clinical trial data between Ipamorelin and Ghrp 2 is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.
Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.
Ipamorelin vs Ghrp 2: Frequently Asked Questions
Ipamorelin is a growth hormone secretagogue (selective ghrp) while GHRP-2 (Pralmorelin) is a growth hormone releasing hexapeptide. They differ in mechanism, dosing, and clinical evidence. Your choice should depend on your specific goals and medical history.
Switching should be done under medical supervision. Your prescriber can advise on transition protocols. Track both in Shotlee for comparison data.
Ipamorelin works as a growth hormone secretagogue (selective ghrp) (200-300 mcg SC 2-3x daily), while GHRP-2 (Pralmorelin) is a growth hormone releasing hexapeptide (100-300 mcg SC 2-3x daily). They have different half-lives (~2 hours vs ~15-30 minutes), side effect profiles, and levels of clinical evidence.
Yes. Shotlee supports tracking any medication or peptide. You can compare your results across different protocols.
Neither is universally better — the right choice depends on your individual health profile, treatment goals, side effect tolerance, insurance coverage, and prescriber recommendation. Clinical trial data shows efficacy differences in specific populations, but personal response varies. Track your experience with either medication in Shotlee to generate objective comparison data with your healthcare provider.
Switching between these medications should be done under medical supervision. Your prescriber will consider factors including your current response, reason for switching, dose equivalence, and transition timing. Use Shotlee to document your outcomes on the current medication so you have a clear baseline for comparison after switching.
Track Ipamorelin or Ghrp 2 in Shotlee
Free dose tracking, side effect logging, and outcome comparison for any medication protocol.